Furthermore, Wilcoxon's test found no significant difference in sensitivity to cabozantinib between GPC-3 positive (average rank 32.27) and GPC-3-negative (average rank 35.63) liver cancer cells (W = 419.500, Z = −0.656, P=0.512). The gene discussed is GPC3; the disease is liver cancer.